Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling

• Published in: Antimicrobial agents and chemotherapy Vol. 66; no. 3; p. e0220321
• Main Authors: Bilal, Hajira, Tait, Jessica R, Lang, Yinzhi, Zhou, Jieqiang, Bergen, Phillip J, Peleg, Anton Y, Bulitta, Jürgen B, Oliver, Antonio, Nation, Roger L, Landersdorfer, Cornelia B
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 15.03.2022
• Subjects: Anti-Bacterial Agents - pharmacology; Anti-Bacterial Agents - therapeutic use; Antimicrobial Chemotherapy; Biofilms; Ceftazidime - pharmacology; Ceftazidime - therapeutic use; Humans; Microbial Sensitivity Tests; Pharmacology; Pseudomonas aeruginosa; Pseudomonas Infections - drug therapy; Pseudomonas Infections - microbiology; Tobramycin - pharmacology; Tobramycin - therapeutic use; mathematical modeling; pharmacokinetics; Pseudomonas aeruginosa; dosage regimen optimization; dynamic infection model; pharmacodynamics

Acute exacerbations of chronic respiratory infections in patients with cystic fibrosis are highly challenging due to hypermutable Pseudomonas aeruginosa, biofilm formation and resistance emergence. We aimed to systematically evaluate the effects of intravenous versus inhaled tobramycin (TOB) with an...